A RARE CASE: RIFAMPIN-INDUCED THROMBOCYTOPENIA
Öz
Aims: Immune thrombocytopenia (ITP) is a hematological disorder characterized by symptoms such as oral bleeding, petechiae, ecchymosis, and nasal bleeding. Tuberculosis remains a prevalent disease in Turkey, and rifampin is an important agent used in its treatment. Although rare, drug- induced ITP cases associated with rifampin use have been reported. This case report aims to draw attention to the possibility of thrombocytopenia developing as a result of rifampin use.
Case: A 76-year-old male patient who had been receiving rifampin treatment following a diagnosis of tuberculosis presented with complaints of gum and nasal bleeding. The patient’s clinical history, physical examination, and laboratory findings were evaluated. Other possible causes of thrombocytopenia, such as pseudothrombocytopenia, myelodysplastic syndrome, and infections, were ruled out. Upon admission, the patient’s platelet count was found to be 3,000/mm³. Rifampin treatment was discontinued, and intravenous immunoglobulin (IVIG) and corticosteroid therapy were initiated. As a result of these treatments, a marked improvement in the patient’s platelet levels was observed.
Conclusion: Although the risk of rifampin-induced ITP is low, it should still be taken into consideration. This case highlights the potential association between rifampin use and thrombocytopenia in a patient presenting with oral bleeding, nasal bleeding, petechiae, and purpura, and aims to inform clinicians of this possibility.
Anahtar Kelimeler
Adverse drug reaction, corticosteroid, immunoglobulin (IVIG), ITP.
Etik Beyan
Bu çalışmanın, özgün bir çalışma olduğunu; çalışmanın hazırlık, veri toplama, analiz ve bilgilerin sunumu olmak üzere tüm aşamalarında bilimsel etik ilke ve kurallarına uygun davrandığımı; bu çalışma kapsamında elde edilmeyen tüm veri ve bilgiler için kaynak gösterdiğime ve bu kaynaklara kaynakçada yer verdiğime; kullanılan verilere herhangi bir değişiklik yapmadığımı, çalışmanın Committee on Publication Ethics (COPE)’in tüm şartlarını ve koşullarını kabul ederek etik görev ve sorumluluklara riayet ettiğimi beyan ederim.
Kaynakça
- 1. Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: A review. World J Gastroenterol. 2014;20:2595–605.
- 2. Koumpis E, Papathanasiou K, Papakonstantinou I, Tassi I, Serpanou A, Kapsali E et al. Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature. EMJ. 2021.
- 3. Verma A, Singh A, Chandra A, Kumar S, Gupta R. Rifampicin-induced thrombocytopenia. Indian J Pharmacol. 2010;42:240–2.
- 4. Dosi R, Chandelkar A, Jain A, Motiwale S, Joshi P, Jain P. Rifampicin-Induced Thrombocytopenia: A Rare Complication. J Assoc Chest Physicians. 2019;7:38–40.
- 5. Kaur A, Bhandari RK, Rohilla R, Shafiq N, Prakash G, Mothsara C et al. Anti-tubercular therapy (ATT) induced thrombocytopenia: A systematic review. Indian J Tuberc. 2023;70:489–96.
- 6. Nagashima A, Kobori T, Hattori M, Imura S, Okochi Y. A Case of Miliary Tuberculosis Complicated by Thyroid Involvement: Managing Rifampicin-Induced Thrombocytopenia With Rifabutin. Cureus. 2024;16(4).
- 7. Chong BH, Young-Ill Choi P, Khachigian L, Perdomo J. Drug-induced Immune Thrombocytopenia. Hematol Oncol Clin North Am. 2013;27:521–40.
- 8. Han R, He H-C, Zhang W-N, Pan Z-T, Feng C-Y, Liang M-J et al. Investigation of the correlation between platelet antibodies and peripheral blood cytopenia in patients with hepatocellular carcinoma. Sci Rep. 2024;14.
- 9. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829–66.
- 10. Choong K, Looke D. Cross-reaction to rifabutin after rifampicin induced flu-like syndrome and thrombocytopenia. Scand J Infect Dis. 2011;43:238.